Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: A novel oral micellar fenretinide formulation with enhanced bioavailability and antitumour activity against multiple tumours from cancer stem cells

Fig. 3

(a) Cytotoxic activity of Bionanofenretinide (Bio-nFeR) in comparison with standard formulation fenretinide (NCI-FeR) in lung CSC. Lung CSC were exposed to the indicated drug doses and cell viability was evaluated by CellTiter-Glo after 72 h and indicated as percentage versus control cells. b Bio-nFeR and NCI-FeR antitumour activity in lung CSC-derived xenografts. (left) Growth curves of lung CSC-derived xenografts in control mice or mice treated with Bio-nFeR or NCI-FeR at 50 mg/kg dose for the indicated times. Lung CSC sample #136 was used for xenograft generation. Mean ± S.D. of three independent experiments is shown. **P < 0.01. (right) Table of drug-induced systemic toxicity in the three groups of mice indicated as percentage of body weight loss (BWL) or number of deaths/total number of mice

Back to article page